| | | | |
| | SCHEDULE 13G | | |
CUSIP No. 05280R 100 | | | | |
(a) | Name of Issuer: Autolus Therapeutics plc |
(b) | Address of Issuer’s principal executive offices: Forest House, 58 Wood Lane, London W12 7RZ, United Kingdom |
(a) | Name of reporting persons filing: |
| (i) | Syncona Portfolio Limited; |
| (ii) | Syncona Holdings Limited; |
| (iii) | Syncona Investment Management Limited; and |
(b) | Address of principal business office or, if none, residence: |
The address of the principal business office of Syncona Portfolio Limited, Syncona Holdings Limited and Synocna Limited is Arnold House, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD, Channel Islands. The address of the principal business office of Syncona Investment Management Limited is 2nd Floor, 8 Bloomsbury Street, London WC1B 3SR, United Kingdom.
Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited’s citizenship is Guernsey. Syncona Investment Management Limited’s citizenship is United Kingdom.
(d) | Title and class of securities: |
Ordinary Shares, nominal value 0.000042 GBP per share, and American Depositary Shares (“ADS”). Each ADS represents one ordinary share, nominal value 0.000042 GBP per share, of the Issuer.
There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the ADS, which are quoted on the Nasdaq Global Select Market under the symbol “AUTL.”
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
Page 6 of 9